Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 3
1955 2
1956 1
1959 1
1960 1
1964 1
1970 1
1976 5
1977 3
1981 2
1982 4
1983 1
1984 2
1985 4
1986 3
1987 2
1988 1
1989 4
1990 1
1991 5
1992 3
1993 2
1994 5
1995 7
1996 4
1997 8
1998 5
1999 5
2000 9
2001 14
2002 4
2003 9
2004 6
2005 4
2006 6
2007 4
2008 3
2009 7
2010 4
2011 11
2012 12
2013 8
2014 5
2015 8
2016 8
2017 11
2018 19
2019 21
2020 29
2021 24
2022 26
2023 25
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Results by year

Filters applied: . Clear all
Page 1
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD. Arbour KC, et al. Among authors: ferrara r. J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20. J Clin Oncol. 2018. PMID: 30125216 Free article.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B. Mezquita L, et al. Among authors: ferrara r. JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. JAMA Oncol. 2018. PMID: 29327044 Free PMC article.
Immunosenescence, inflammaging, and cancer immunotherapy efficacy.
Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, Besse B, Ferrara R, Chaput N, Baldini C. Rodriguez JE, et al. Among authors: ferrara r. Expert Rev Anticancer Ther. 2022 Sep;22(9):915-926. doi: 10.1080/14737140.2022.2098718. Epub 2022 Jul 14. Expert Rev Anticancer Ther. 2022. PMID: 35815381 Review.
Eating away T cell responses in lung cancer.
Ferrara R, Roz L. Ferrara R, et al. J Exp Med. 2022 Dec 5;219(12):e20221449. doi: 10.1084/jem.20221449. Epub 2022 Oct 10. J Exp Med. 2022. PMID: 36214813 Free PMC article.
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.
Soo RA, Martini JF, van der Wekken AJ, Teraoka S, Ferrara R, Shaw AT, Shepard D, Calella AM, Polli A, Toffalorio F, Tomasini P, Chiu CH, Kowalski DM, Kim HR, Solomon BJ. Soo RA, et al. Among authors: ferrara r. J Thorac Oncol. 2023 Nov;18(11):1568-1580. doi: 10.1016/j.jtho.2023.05.021. Epub 2023 Jun 7. J Thorac Oncol. 2023. PMID: 37295609 Free article.
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?
Venanzi FM, Bini M, Nuccio A, De Toma A, Lambertini M, Ogliari FR, Oresti S, Viganò MG, Brioschi E, Polignano M, Naldini MM, Riva S, Ferrara M, Fogale N, Damiano G, Russo V, Reni M, Veronesi G, Foggetti G, Conforti F, Bulotta A, Ferrara R. Venanzi FM, et al. Among authors: ferrara r. Cancer Treat Rev. 2023 Dec;121:102648. doi: 10.1016/j.ctrv.2023.102648. Epub 2023 Oct 26. Cancer Treat Rev. 2023. PMID: 37918169 Review.
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Piccirillo MC, et al. Among authors: ferrara r. J Thorac Oncol. 2023 Jun;18(6):813-819. doi: 10.1016/j.jtho.2023.02.003. Epub 2023 Feb 24. J Thorac Oncol. 2023. PMID: 36841541 Clinical Trial.
341 results